Deferasirox Supplier in Iran
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to IFDA-registered importers.
Supply & Market
Taj Pharma supplies WHO-GMP Deferasirox dispersible tablets to Iran through Gulf-region wholesalers, hospital pharmacies and Ministry-of-Health tenders. Shipments to Taj Pharma India Ltd. arrive via Jebel Ali, Dammam, Aqaba and Beirut, with full Arabic / English secondary-pack labelling on request.
The Iran market for iron-chelation therapy is driven by a high regional prevalence of thalassemia and other transfusion-dependent anaemias, where Deferasirox is the preferred once-daily oral chelator.
Our regulatory and commercial team in Mumbai partners directly with importers, hospital procurement officers and Ministry-of-Health tender desks across Iran — from Tehran to regional referral centres — for streamlined supply continuity.
Supply Capability for Iran
DEFRATAJ is supplied to Iran across all five strengths — 100 mg, 125 mg, 250 mg, 400 mg and 500 mg dispersible tablets — in HDPE bottles (30s/60s/100s) and Alu-Alu blister packs. Minimum-order quantities start at 50,000 tablets per strength with a typical lead time of 4–6 weeks from PO confirmation.
- Strengths shipped: 100 mg, 125 mg, 250 mg, 400 mg, 500 mg dispersible tablets
- Pack sizes: bottles (30/60/100 tabs), Alu-Alu blisters (10x10), hospital institutional packs
- MOQ: 50,000 tablets per strength per shipment (mixed pallets supported)
- Lead time: 4–6 weeks ex-Mumbai (JNPT / Nhava Sheva)
- Shelf life: 24 months at 25°C / 60% RH (Zone IVb stability data on file)
- Documents per shipment: CoA, CoO, packing list, invoice, BL/AWB, free-sale certificate
- Private label / co-branding: available with own artwork and brand registration
Cold-chain is not required for dispersible tablets, but climatised containers can be arranged on request for hot-route lanes into Iran.
Regulatory Pathway in Iran
Deferasirox dispersible tablets are registered in Iran with the Iran Food and Drug Administration (IFDA). Taj Pharma submits the full CTD dossier (Modules 1–5) along with our WHO-GMP certificate, CoPP, manufacturing licence, plant master file and validated stability data to IFDA. Our regulatory desk handles queries, sample submissions and post-approval variations on behalf of local marketing-authorisation holders.
Local agent appointment, secondary packaging in Persian, and pharmacovigilance reporting are all coordinated from our Mumbai head office. Documentation can be couriered or e-submitted to IFDA in Tehran.
- CTD dossier (Modules 1–5) ready
- WHO-GMP · ISO 9001 · PIC/S-aligned plant
- CoPP & manufacturing licence on request
- Stability data (long-term & accelerated, Zone IVb)
- Country code
IR· trade currency Iranian Rial